Aurealis News
Aurealis Therapeutics to Attend Swiss Biotech Day 2025
Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, announced today that Chief Operating Officer Laurent Décory will...
Aurealis Therapeutics Concludes Largest EWMA Participation to Date with Exciting Investigator Data of DIAMEND Phase 2 DFU Clinical Trial Presented by Prof. Alberto Piaggesi
Watch highlights video here. Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, proudly concludes its most significant...
Aurealis Therapeutics Raises CHF 8 Million to Complete Phase 2 Clinical Studies in Chronic Wounds and Accelerate Oncology Program
Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, has raised CHF 8 million from existing investors...
Aurealis Therapeutics Announces Peer-Reviewed Paper Published from Phase 1 Study of AUP-16 for Non-Healing Diabetic Foot Ulcers
Aurealis Therapeutics, a clinical-stage Swiss-Finnish company developing multi-target cell and gene therapies for chronic wounds and cancer, is proud to announce the publication of its AUP-16 Phase 1 clinical trial...
Aurealis Therapeutics Announces Last Patient Last Treatment in DIAMEND Phase 2 Diabetic Foot Ulcer Clinical Trial of AUP-16
Aurealis Therapeutics, a clinical-stage Swiss-Finnish company developing multi-target cell and gene therapies for chronic wounds and cancer, is pleased to announce that the last patient in its DIAMEND AUP-16 Phase...
Aurealis Therapeutics Proudly Sponsors EWMA Diabetic Foot Committee
Aurealis Therapeutics is pleased to announce our sponsorship of the newly established EWMA Diabetic Foot Committee, an initiative launched by the European Wound Management Association (EWMA) in 2023. This committee...